Mesothelin-CAR-hMSCs with PD-1/TGF-β inhibition for solid tumor therapy
Innovative M-CAR-hMSCs engineered to overcome solid tumor challenges by inhibiting PD-1 and TGF-β pathways, optimizing CARs for enhanced tumor infiltration and exhaustion resistance. Validated in microfluidic models for ...